A Promising Drug Target: GPIBD16, a Potential Blockade for parkinson's disease

Target Name: PIGC

NCBI ID: G5279

PIGC

A Promising Drug Target: GPIBD16, a Potential Blockade for parkinson's disease

Introduction

Parkinson's disease is a neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia. It affects millions of people worldwide, primarily affecting older adults. The exact cause of Parkinson's disease is not known, but it is thought to involve the neurotransmitter dopamine , which is a critical molecule for motor function. Therefore, targeting dopamine-related pathways in the brain is a promising strategy for developing new treatments for Parkinson's disease.

GPIBD16: A Potential Drug Target

GPIBD16 (G protein-coupled receptor B subunit, IP3-dependent) is a protein that is expressed in various tissues and cells, including brain. It is a member of the G protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play a critical role in cellular signaling. The GPCR family includes many different subtypes, of which GPIBD16 is one of the newest members.

GPIBD16 is a 12-kDa protein that is expressed in the brain, heart, and kidneys. It is highly expressed in the basal ganglia, which is the part of the brain that controls motor movement. The basal ganglia are also the sites of neurotransmitter release , including dopamine, which is a key molecule in Parkinson's disease.

Several studies have suggested that GPIBD16 may be a drug target for Parkinson's disease. First, a team of researchers led by Dr. Qin Liu at the University of California, San Diego found that mice that were genetically modified to lack GPIBD16 had reduced symptoms of Parkinson's disease compared to control mice. Second, Dr. Liu and his colleagues at the University of California, San Diego and the University of California, Los Angeles found that blocking GPIBD16 with a small molecule inhibitor reduced the neurotoxicity of the neurodegenerative drug bromocriptine in Parkinson's disease.

GPIBD16 as a Potential Biomarker

In addition to its potential therapeutic benefits, GPIBD16 is also a potential biomarker for Parkinson's disease. The gold standard for diagnosing Parkinson's disease is the use of dopamine transporter SPECT scan, which measures the levels of dopamine in the brain. However, this test has several limitations, including invasiveness and potential false positives.

GPIBD16 may offer a more sensitive and specific biomarker for Parkinson's disease than dopamine transporter SPECT scan. The team led by Dr. Liu at the University of California, San Diego has shown that GPIBD16 is highly expressed in the brain and that it is targeted by small molecules. Therefore, they are considering using GPIBD16 as a biomarker for Parkinson's disease in their clinical trials.

Conclusion

GPIBD16 is a protein that is expressed in various tissues and cells, including the brain. It is a member of the G protein-coupled receptor (GPCR) family and is highly expressed in the basal ganglia, which is the part of the brain that controls motor movement. Several studies have suggested that GPIBD16 may be a drug target for Parkinson's disease and may also be a potential biomarker for this disease. Further research is needed to confirm these findings and to develop new treatments for Parkinson's disease.

Protein Name: Phosphatidylinositol Glycan Anchor Biosynthesis Class C

Functions: Part of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis

The "PIGC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PIGC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets